UCB U.S. News

UCB's Global Corporate Website

Welcome to UCB in the United States

Healthcare Professionals

Patients

Investors

17 5 U.S. Organizations Receive Support from UCB Community Health Fund

Read More Share:

Jan

06 UCB announces rozanolixizumab BLA for the treatment of generalized myasthenia gravis filed with U.S. FDA and designated for Priority Review

Read More Share:

Dec

23 UCB Announces FDA Acceptance of BLA Resubmission for Bimekizumab

Read More Share:

Nov

22 UCB Submits Response to FDA Complete Response Letter for Bimekizumab

Read More Share:

Nov

17 Shaping the Future of Psoriatic Arthritis Care in Rural Settings

Read More Share:

Nov

14 UCB announces U.S. FDA acceptance of new drug application and EMA MAA validation for zilucoplan for the treatment of generalized myasthenia gravis in adult patients

Read More Share:

Nov

10 Bimekizumab Demonstrated Sustained Clinical Responses to Week 52 in Phase 3 Studies in Psoriatic Arthritis, Non-Radiographic Axial Spondyloarthritis, and Ankylosing Spondylitis

Read More Share:

Nov

09 Moving the Conversation Forward in Rheumatology – UCB at ACR Convergence 2022

Read More Share:

Nov

08 UCB Reinforces Commitment to Rheumatology With 15 Abstracts Including New Late-Breaking Data at ACR Convergence 2022

Read More Share:

Sep

26 UCB U.S. Headquarters in Atlanta Awarded Prestigious LEED Gold WELL Platinum Certifications

Read More Share:

Categories

Archives

Jan

17

5 U.S. Organizations Receive Support from UCB Community Health Fund

Jan

06

UCB announces rozanolixizumab BLA for the treatment of generalized myasthenia gravis filed with U.S. FDA and designated for Priority Review

Dec

23

UCB Announces FDA Acceptance of BLA Resubmission for Bimekizumab

Nov

22

UCB Submits Response to FDA Complete Response Letter for Bimekizumab

Nov

17

Shaping the Future of Psoriatic Arthritis Care in Rural Settings

Nov

14

UCB announces U.S. FDA acceptance of new drug application and EMA MAA validation for zilucoplan for the treatment of generalized myasthenia gravis in adult patients

Nov

10

Bimekizumab Demonstrated Sustained Clinical Responses to Week 52 in Phase 3 Studies in Psoriatic Arthritis, Non-Radiographic Axial Spondyloarthritis, and Ankylosing Spondylitis

Nov

09

Moving the Conversation Forward in Rheumatology – UCB at ACR Convergence 2022

Nov

08

UCB Reinforces Commitment to Rheumatology With 15 Abstracts Including New Late-Breaking Data at ACR Convergence 2022

Sep

26

UCB U.S. Headquarters in Atlanta Awarded Prestigious LEED Gold WELL Platinum Certifications

Choose Country

UCB in the U.S.

Innovation

Disease Areas

Sustainability

Newsroom

Contact

Categories

Archives

Jan

17

5 U.S. Organizations Receive Support from UCB Community Health Fund

Jan

06

UCB announces rozanolixizumab BLA for the treatment of generalized myasthenia gravis filed with U.S. FDA and designated for Priority Review

Dec

23

UCB Announces FDA Acceptance of BLA Resubmission for Bimekizumab

Nov

22

UCB Submits Response to FDA Complete Response Letter for Bimekizumab

Nov

17

Shaping the Future of Psoriatic Arthritis Care in Rural Settings

Nov

14

UCB announces U.S. FDA acceptance of new drug application and EMA MAA validation for zilucoplan for the treatment of generalized myasthenia gravis in adult patients

Nov

10

Bimekizumab Demonstrated Sustained Clinical Responses to Week 52 in Phase 3 Studies in Psoriatic Arthritis, Non-Radiographic Axial Spondyloarthritis, and Ankylosing Spondylitis

Nov

09

Moving the Conversation Forward in Rheumatology – UCB at ACR Convergence 2022

Nov

08

UCB Reinforces Commitment to Rheumatology With 15 Abstracts Including New Late-Breaking Data at ACR Convergence 2022

Sep

26

UCB U.S. Headquarters in Atlanta Awarded Prestigious LEED Gold WELL Platinum Certifications

Choose Country

UCB in the U.S.

Innovation

Disease Areas

UCB Worldwide

Sustainability

Newsroom

Contact